Contact MENU

Pipeline

We’re excited about the products we have in the pipeline and the impact they will have on patients.

Product Indication Preclin Phase One Phase Two Phase Three
KIO-101 (Eyedrop) Dry Eye Disease
 
 
 
 
KIO-201 (Eyedrop) PRK Surgical Recovery
 
 
 
 
KIO-301 (Intravitreal) Retinitis Pigmentosa
 
 
 
 
KIO-102 (Oral) Autoimmune Diseases
 
 
 
 
These therapeutics are still in development and are not yet approved for commercial use.
NEWS
Kiora Pharma - Eye Treatment
11.15.21

Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

SALT LAKE CITY, UT, Nov 15, 2021 – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today reported its financial results for the quarter ended September 30, 2021 and...
Read more
Kiora Eyegate PR - Child Eye Exam
11.06.21

EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy

SALT LAKE CITY, UT, November 8, 2021 – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG). Kiora will trade...
Read more
10.26.21

EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc.

EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline WALTHAM, MA, October 26, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical...
Read more